Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02008279 · ClinicalTrials.gov registry record · Phase 1

A Safety and Pharmacokinetics Study of CNTO 3157 in Healthy Japanese and Caucasian Participants

A Phase 1 study of Healthy, sponsored by Janssen Research & Development.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target
1
Study location

NCT02008279 is a Phase 1 study of Healthy that has completed, run by Janssen Research & Development. The registered enrollment target is 40 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02008279, a Phase 1 study of Healthy, has completed, sponsored by Janssen Research & Development.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to find out if different doses of CNTO 3157 are well tolerated in both Japanese and Caucasian men as well as to understand how the body absorbs and removes the study drug after being injected or infused into the body.

Conditions Studied

Interventions

  • DRUG Placebo
  • BIOLOGICAL 100 mg CNTO 3157
  • BIOLOGICAL 300 mg CNTO 3157
  • BIOLOGICAL 600 mg CNTO 3157

Study Locations (1)

California

  • - Cypress

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2013-12
Est. Completion 2014-08
Phase Phase 1

Sponsor

Janssen Research & Development

593 total trials

What the Registry Record Tells You About NCT02008279

The ClinicalTrials.gov registry entry for NCT02008279 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT02008279 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT02008279 about?

NCT02008279 is a clinical study titled "A Safety and Pharmacokinetics Study of CNTO 3157 in Healthy Japanese and Caucasian Participants". The purpose of this study is to find out if different doses of CNTO 3157 are well tolerated in both Japanese and Caucasian men as well as to understand how the body absorbs and removes the study drug after being injected or infused into the body.

What is the current status of trial NCT02008279?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2013-12. Estimated completion is 2014-08.

What conditions does trial NCT02008279 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT02008279?

The interventions under investigation include: Placebo (DRUG), 100 mg CNTO 3157 (BIOLOGICAL), 300 mg CNTO 3157 (BIOLOGICAL), 600 mg CNTO 3157 (BIOLOGICAL).

Who is sponsoring clinical trial NCT02008279?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02008279 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.